---
title: Resources
description: Browse and filter OM1 resources
category: CustomType
canonical_url: https://www.om1.com/resources/
source: om1
license: © 2026 OM1. All rights reserved.
slug: resources
id: 5IiiHICZtQQATqj0uQ4JW6
contentType: customType
---

# Resources

Browse and filter OM1 resources

![Wheel Resources Starburst Blue](https://images.ctfassets.net/ddhe5ahaolzf/4WJMOR3GD2idS8HXyRjONX/1d8d38d1f5458d702a8217e2657e0242/wheel-resources-starburst-blue.svg)

## Resource Library

- [Can artificial intelligence reduce racial and ethnic disparities in Fabry disease diagnosis?](/resources/publications/other/can-artificial-intelligence-reduce-racial-and-ethnic-disparities-in-fabry/)
- [Baseline Characteristics Among Early Initiators of Donanemab In the U.S.: A Real-world Study](/resources/publications/other/baseline-characteristics-among-early-initiators-of-donanemab-in-the-u-s-a/)
- [Bringing Treatment-Resistant Depression to Light: AI-Driven Patient Discovery in Real-World Data](/resources/case-studies/ai/bringing-treatment-resistant-depression-to-light-ai-driven-patient-discovery-in-real-world-data/)
- [Using Artificial Intelligence to Find Undiagnosed Generalized Pustular Psoriasis Patients](/resources/case-studies/ai/using-artificial-intelligence-to-find-undiagnosed-generalized-pustular/)
- [Patient Identification in Rare Diseases](/resources/case-studies/ai/patient-identification-in-rare-diseases/)
- [Supporting payer adoption with real-world evidence: Nalu Medical demonstrates value with OM1 data](/resources/case-studies/data/supporting-payer-adoption-with-real-world-evidence-nalu-medical-demonstrates/)
- [Precision Targeting: Uncovering High-Value HCPs with AI](/resources/case-studies/ai/precision-targeting-uncovering-high-value-hcps-with-ai/)
- [FDA Draft Guidance Signals a New Era for Post-Approval Data in Cell & Gene Therapy](/resources/blogs/registries/fda-draft-guidance-signals-a-new-era-for-post-approval-data-in-cell-gene-therapy/)
- [Leveraging Real-World and Passive Data to Significantly Improve Site Satisfaction and Reduce Trial Costs](/resources/blogs/other/leveraging-real-world-and-passive-data-to-significantly-improve-site-satisfaction-and-reduce-trial-costs/)
- [Why Patient Registries Are Rapidly Rising Back in Importance](/resources/blogs/other/why-patient-registries-are-rapidly-rising-back-in-importance/)
- [Mapping the full patient journey in rheumatology: RWD and AI in Action](/resources/blogs/other/mapping-the-full-patient-journey-in-rheumatology-rwd-and-ai-in-action/)
- [Real-World Evidence and the Five Vs (Velocity, Volume, Variety, Veracity, and Value)](/resources/blogs/other/real-world-evidence-and-the-five-vs-velocity-volume-variety-veracity-and-value/)
- [Enhancing Patient Journeys in Clinical Research with AI-Phenotyping](/resources/blogs/other/enhancing-patient-journeys-in-clinical-research-with-ai-phenotyping/)
- [Leveraging AI to Amplify PHQ-9 Endpoint Availability for Improving Depression Research](/resources/blogs/other/leveraging-ai-to-amplify-phq-9-endpoint-availability-for-improving-depression-research/)
- [Using Real-World Data and AI to Phenotype HFpEF Patients and Advance HF Research](/resources/blogs/other/using-real-world-data-and-ai-to-phenotype-hfpef-patients-and-advance-hf-research/)
- [Integrated Real-World Evidence Generation for Regulatory and Other Research](/resources/blogs/other/integrated-real-world-evidence-generation-for-regulatory-and-other-research/)
- [National Minority Health Month: Better Health Through Better Understanding](/resources/blogs/other/national-minority-health-month-better-health-through-better-understanding/)
- [Clinical Relevance of a Machine Learning Model for Automated Analyses of Depression Severity: the ePHQ-9 in Treatment-Resistant Depression](/resources/publications/other/ml-epnq9-depression-severity-trd/)
- [Analytic Approaches to Handling Missing Data in Observational Studies.](https://ww2.amstat.org/meetings/biopharmworkshop/2016/index.cfm?fuseaction=AbstractDetails&AbstractID=300198)
- [Registry of Patient Registries Outcome Measures Framework: Information Model Report.](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/ropr-methods-information-model-report_4.pdf)
- [Development of Harmonized Outcome Measures for Use in Patient Registries and Clinical Practice: Methods and Lessons Learned. Final Report](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/white-paper-standardized-library_0.pdf)
- [A New Approach to Identifying Patients with Elevated Risk for Fabry Disease Using a Machine Learning Algorithm.](https://ojrd.biomedcentral.com/articles/10.1186/s13023-021-02150-3)
- [Comparison of Resource Utilization and Clinical Outcomes Following Screening with Digital Breast Tomosynthesis Versus Digital Mammography: Findings From a Learning Health System](https://pubmed.ncbi.nlm.nih.gov/30057195/)
- [Standardized Library of Asthma Outcome Measures](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/white-paper-library-asthma.pdf)
- [Real-World Evidence Analysis of the Impact of Steroid-Eluting Implants on Healthcare Resource Use Among Chronic Rhinosinusitis Patients Undergoing Sinus Surgery](https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.2022874?needAccess=true)
- [Reduction in healthcare resource use through 24 months following sinus surgery with steroid-eluting implants in chronic rhinosinusitis patients with and without nasal polyps: a real-world study](https://www.tandfonline.com/doi/epdf/10.1080/03007995.2023.2194776?needAccess=true)
- [Predicting Disease Progression in Non-Alcoholic Steatohepatitis (NASH) Patients with Early Stage Fibrosis Within a Large, Representative Real-World Database of US Patients](https://www.gastrojournal.org/article/S0016-5085(21)02555-5/pdf?referrer=https%3A%2F%2Fwww.gastrojournal.org%2F)
- [A Highly Predictive Machine Learning Model to Identify Hospitalized Patients at Risk for 30-day Readmission or Mortality](https://www.jacc.org/doi/10.1016/s0735-1097%2818%2932275-7?types=publications&count=126)
- [Standardized Library of Atrial Fibrillation Outcome Measures. Research White Paper.](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/white-paper-library-afib.pdf)
- [Harmonized Outcome Measures for Use in Atrial Fibrillation Patient Registries and Clinical Practice](https://www.ncbi.nlm.nih.gov/pubmed/30449519)
- [Validation of a Machine Learning Approach to Estimate Expanded Disability Status Scale Scores for Multiple Sclerosis.](https://journals.sagepub.com/doi/epub/10.1177/20552173221108635)
- [Real-world healthcare utilization and costs of peripheral nerve stimulation with a micro-IPG system](https://www.tandfonline.com/doi/epdf/10.1080/17581869.2025.2449810?needAccess=true)
- [Weight Gain and Comorbidities Associated With Oral Second-Generation Antipsychotics: Analysis of Real-World Data for Patients With Bipolar I Disorder or Schizophrenia](https://link.springer.com/article/10.1186/s12888-022-03758-w)
- [A machine learning model using clinical notes to estimate PHQ-9 symptom severity scores in depressed patients](https://www.sciencedirect.com/science/article/abs/pii/S016503272500182X?via%3Dihub)
- [Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States](https://www.tandfonline.com/doi/full/10.1080/13696998.2025.2513766)
- [Clinical burden of major depressive disorder with versus without prominent anhedonia using a real-world electronic health records and claims linked database](https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-025-07139-x)
- [Impact of New Guidelines for High Blood Pressure: Findings from the OM1 Intelligent Data Cloud](/resources/publications/data/new-guidelines-high-bp-impact-rwd/)
- [Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence](/resources/publications/data/assessing-rwd-quality-registry-criteria/)
- [Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice](/resources/publications/data/harmonized-outcomes-nsclc-registries/)
- [Representation of patients of minority race and ethnicity in real-world databases and tumor registries of patients with breast cancer](/resources/publications/data/minority-race-representation-breast-cancer-rwd/)
- [Mammography screening outcomes for women screened by standard versus high resolution digital breast tomosynthesis](/resources/publications/registries/mammography-outcomes-standard-vs-high-res-dbt/)
- [Management of HS by Dermatologists and Rheumatologists](/resources/publications/data/hs-management-dermatologists-rheumatologists/)
- [Using AI to Predict Progression from Psoriasis to Psoriatic Arthritis in a Real-World Dataset.](/resources/publications/ai/ai-predict-psoriasis-to-psa-progression/)
- [Machine Learning Generated Risk Model to Predict Unplanned Hospital Admission in Heart Failure](/resources/publications/ai/ml-risk-model-heart-failure-hospital-admission/)
- [Using Real-World Data and Digital Phenotyping to Identify Candidates for anti-CGRP Migraine Treatment](/resources/publications/data/digital-phenotyping-cgrp-migraine-candidates/)
- [Diagnosis of Frontotemporal Dementia is Often in Non-Specialist Settings and Complicated by Non-FTD Dementia and Psychiatric Diagnoses](/resources/publications/data/ftd-diagnosis-non-specialist-settings/)
- [Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practices](/resources/publications/data/harmonized-outcomes-depression-registries/)
- [Reductions in Depressive Symptoms After Brexpiprazole Augmentation Among Patients with Major Depressive Disorder Receiving Antidepressant Therapy in Real-World Settings](/resources/publications/data/brexpiprazole-mdd-augmentation-rwd/)
- [Development of a Machine Learning Model for Estimating CGI-I Scores Using Electronic Medical Records from Real-World Data Sources in Schizophrenia, Bipolar I and Major Depressive Disorder](/resources/publications/ai/ml-cgi-i-schizophrenia-bipolar-mdd-rwd/)
- [Comparing Confidence Intervals of Incidence Rates.](https://www.valueinhealthjournal.com/article/S1098-3015(16)01781-2/pdf)
- [Towards Personalized Breast Imaging Pathways: Initial Findings from a Learning Health System.](/resources/publications/registries/personalized-breast-imaging-pathways-l/)
- [Disparities in Accessing Screening Mammography: Opportunities for Improving Diagnostic Outcomes](/resources/publications/registries/disparities-access-screening-mammography-diagnostic/)
- [Using Real-World Evidence to Support a Changing Paradigm for Cancer Screening: A Commentary](/resources/publications/registries/rwe-support-cancer-screening-paradigm/)
- [Outcomes by Race in Breast Cancer Screening With Digital Breast Tomosynthesis Versus Digital Mammography](https://www.jacr.org/action/showPdf?pii=S1546-1440%2821%2900006-5)
- [Method to Derive a Modified Mayo Score from Electronic Health Records Data](/resources/publications/data/method-derive-modified-mayo-score-from-ehr/)
- [Treatment Supplementation Following Dupilumab Initiation in Real-World Patients With Atopic Dermatitis in the U.S.](/resources/publications/data/dupilumab-supplementation-atopic-dermatitis-rwd/)
- [A Real World Analysis of Apremilast and Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis, Including Impact on Weight Loss by Diabetic Status](/resources/publications/data/apremilast-cardiometabolic-weight-loss-rwd/)
- [Natural History of Keloids: A Sociodemographic Analysis Using Structured and Unstructured Data](https://link.springer.com/article/10.1007/s13555-023-01070-3)
- [Real-World Dupilumab Continuation in US Adults With Atopic Dermatitis Over a 24-Month Period](/resources/publications/data/dupilumab-continuation-adult-atopic-dermatitis/)
- [Findings From a Non-Alcoholic Steatohepatitis (NASH) Cohort Developed via Artificial Intelligence in a Large Representative Population in the U.S.](/resources/publications/ai/ai-developed-nash-cohort-findings-rwd/)
- [Characteristics of Asymptomatic Heart Failure Patients with Reduced Ejection Fraction in a Large US-Based Real-World Cohort](/resources/publications/data/asymptomatic-heart-failure-reduced-ef-rwd/)
- [Defining Provider Prescribing Preference as an Instrumental Variable: A Case Study of NOACs in Stroke Prevention](/resources/publications/data/provider-preference-instrumental-variable-noacs/)
- [Application of E-Value Analysis to Gauge Unmeasured Confounding in Real-World Data (RWD) Studies](/resources/publications/registries/evalue-analysis-unmeasured-confounding-rwd/)
- [Impact of Population Characteristic on Recall Rates: Initial Finding from a Learning Health System](/resources/publications/data/population-characteristic-recall-rates-lhs/)
- [Effect of Breast Cancer Screening Modality Order on Recall, Cancer Detection Rates, and Positive Predictive Value 1 for Women with Multiple Screening Exams](/resources/publications/registries/breast-cancer-screening-modality-order-impact/)
- [Method To Derive A Crohn’s Disease Activity Index From Electronic Health Records Data](/resources/publications/data/method-derive-cdai-from-ehr/)
- [Harmonized Outcome Measures for Use in Asthma Patient Registries and Clinical Practice](/resources/publications/data/harmonized-outcomes-asthma-registries/)
- [Real-World Use of Biologics and Prescription Topical Medications in Pediatric Psoriasis in a Large Dermatology Network in the U.S.](/resources/publications/data/pediatric-psoriasis-biologics-topicals-rwd/)
- [Characterization of Patients with Co-morbid Dermatological and Mental Health Conditions](https://www.jaad.org/article/S0190-9622(23)01459-7/fulltext)
- [Comparison of Improvements in Psoriatic Arthritis Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice](/resources/publications/data/psa-bdmard-class-comparison-disease-activity/)
- [Patient-Reported Outcomes and Changes in DMARD Therapy Among Psoriatic Arthritis Patients Treated in Routine Clinical Practice.](/resources/publications/data/psa-pros-dmard-therapy-changes-rwd/)
- [Real-World Characterization and Management of Alopecia Areata Patients in the U.S.](/resources/publications/data/alopecia-areata-management-rwd-characterization/)
- [Patient Characteristics and Social Determinants of Health in a Large Real-World Cohort of Vitiligo Patients in the U.S.](/resources/publications/data/sdoh-vitiligo-patient-characteristics-rwd/)
- [Real-World Dupilumab Continuation in US Children and Adolescents With Atopic Dermatitis Over a 24-Month Period](/resources/publications/data/dupilumab-continuation-pediatric-atopic-dermatitis/)
- [Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting.](/resources/publications/data/apremilast-cardiometabolic-psoriasis-psa-rwd/)
- [Identifying Progressing Patients in an Artificial Intelligence (AI) Based Cohort of Nonalcoholic Steatohepatitis (NASH)](/resources/publications/ai/ai-identifying-nash-progressing-patients/)
- [Variation in Outcome Measures in Atrial Fibrillation Registries and the Need for Harmonization](/resources/publications/data/outcome-measure-variation-afib-harmonization-need/)
- [The Association Between Social Determinants of Health and 1-Year Survival Among Patients with Heart Failure in a Real-World Cohort](/resources/publications/data/sdoh-heart-failure-1-year-survival-rwd/)
- [Real-World Switching Patterns Among US Generic Glatiramer Acetate Multiple Sclerosis Patients](/resources/publications/data/ms-generic-glatiramer-switching-rwd/)
- [Revisiting MS Prevalence in the 21st Century: Exploration Based on a Large Representative US-Based Real-World Cohort](/resources/publications/data/ms-prevalence-21st-century-rwd/)
- [Predicting Relapse Episodes in Patients with Multiple Sclerosis Treated with Disease Modifying Therapies in a Large Representative US-Based Real World Cohort](/resources/publications/ai/ms-predicting-relapse-episodes-rwd/)
- [Treatment Patterns and Reasons for Switching among U.S. Patients with Multiple Sclerosis Taking the Glatiramer Acetate Class of Products](/resources/publications/data/ms-glatiramer-treatment-switching-patterns/)
- [A Real-World Retrospective Analysis of Outcomes in Multiple Sclerosis Patients Who Transitioned to Alemtuzumab After Rituximab or Ocrelizumab](/resources/publications/data/ms-alemtuzumab-transition-outcomes/)
- [Comparison of Symptoms, Treatments, and Healthcare Resource Utilization in Patients with Multiple Sclerosis by Sex in a Real-World Cohort in the U.S.](/resources/publications/data/ms-sex-differences-hcu-rwd-cohort/)
- [Assessing Comorbid Behavioral Health Conditions, Healthcare Resource Utilization, and Medication Use in Patients Seeking Mental Health Care within a Large, Representative Real-World Multiple Sclerosis Registry](/resources/publications/data/ms-comorbid-behavioral-health-hcu-registry/)
- [Real-World Adherence, Discontinuation, and Switching among Patients with Multiple Sclerosis Initiating Generic Glatiramer Acetate from Two Large Real-world Databases in the United States](/resources/publications/other/ms-generic-glatiramer-adherence-switching/)
- [Assessing the Expanded Disability Status Scale in Secondary Progressive Multiple Sclerosis Patients Treated with Disease Modifying Therapies within a Large, Representative Real World Multiple Sclerosis Registry](/resources/publications/data/spms-edss-dmt-treatment-registry/)
- [Characterizing Disease Progression in Multiple Sclerosis Subtypes Using RWD: Feasibility of Applying a Machine Learning Model to Address Missing Data](/resources/publications/ai/ms-progression-subtypes-ml-missing-data/)
- [Patient and Provider Characteristics Associated with PHQ-9 Administration and Outcomes Assessment in Routine Clinical Practice](/resources/publications/neuro/neuroscience-inc-ms/)
- [Patient & Provider Characteristics Associated with PHQ-9 Administration and Outcomes Assessment in Routine Clinical Practice: Findings from the OM1 Intelligent Data Cloud](/resources/publications/data/phq9-admin-patient-provider-characteristics-rwd/)
- [Depression and Patient Outcomes Among Rheumatoid Arthritis Patients in a Large US-Based Real World Cohort](/resources/publications/data/depression-outcomes-ra-rwd-cohort/)
- [Evaluating the Feasibility of Capturing a Core Set of Harmonized Depression Outcome Measures in Primary Care and Mental Health Patient Registries](/resources/publications/data/core-harmonized-depression-outcomes-registry-feasibility/)
- [Weight Gain and Treatment Interruptions With Second-Generation Oral Antipsychotics: Analysis of Real-World Data Among Patients With Schizophrenia or Bipolar I Disorder](/resources/publications/data/antipsychotics-weight-gain-interruptions-rwd/)
- [Use of a Natural Language Processing-Based Approach to Extract Depression Symptom Severity and Suicide Ideation from Clinical Notes to Support Depression Research](/resources/publications/ai/nlp-extract-suicide-ideation-clinical-notes/)
- [Changes in Weight Across the Life Span in Patients with Bipolar Disorder I Treated with Second Generation Antipsychotics](/resources/publications/data/bipolar-i-antipsychotic-weight-change-lifespan/)
- [The Association Between Race, Social Determinants of Health, and Treatment for Major Depressive Disorder (MDD) in a Real-World Cohort](/resources/publications/data/race-sdoh-mdd-treatment-rwd/)
- [The Association Between Credit Risk Score and Major Depressive Disorder Burden Using a Machine Learning Estimation of the PHQ-9 in a Real-World Cohort](/resources/publications/ai/credit-score-mdd-burden-ml-ephq9/)
- [Development of a Machine Learning Model for Estimating PHQ-9 Scores Using Clinical Notes from Real-World Data Sources](/resources/publications/ai/ml-estimate-phq9-clinical-notes-rwd/)
- [Use of Medical Language Processing in Real-World Data to Understand Antidepressant Side Effects and Improve Research in Mental Health](/resources/publications/ai/nlp-antidepressant-side-effects-mental-health-rwd/)
- [Identification of Treatment Resistant Major Depressive Disorder using a Machine Learning Algorithm](/resources/publications/ai/ml-trd-identification-algorithm/)
- [Addressing Gaps in Real-World Data Sources through Automated Extraction of Psychiatric Comorbidities and Medication Side Effects from Clinical Notes](/resources/publications/data/ai-extract-psychiatric-comorbidities-clinical-notes/)
- [he Association Between Adherence to Esketamine Nasal Spray Therapy Dosing Regimen and Changes in Depressive Symptoms Among Patients With Treatment-Resistant Depression in the U.S.](/resources/publications/data/esketamine-adherence-trd-symptom-change/)
- [Suicidal Ideation in Patients Treated with Glucagon-like Peptide 1 Receptor (GLP1) Agonists: A Retrospective Real-World Analysis](/resources/publications/data/glp1-agonists-suicidal-ideation-rwd-analysis/)
- [AI-Based Estimation of the CGI-I to Address Gaps in Real-World Data and Increase Study Sample Size](/resources/publications/ai/ai-estimation-cgi-i-rwd-gap-filling/)
- [Patient Reported Outcomes and Changes in DMARD Therapy for Rheumatoid Arthritis in Routine Clinical Practice](/resources/publications/data/ra-pros-dmard-therapy-changes-rwd/)
- [Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Next Generation Registry](/resources/publications/data/bdmard-initiation-disease-activity-next-gen-registry/)
- [Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort](https://acrabstracts.org/abstract/comparison-of-improvements-in-disease-activity-between-classes-of-biologic-disease-modifying-anti-rheumatic-drugs-in-routine-clinical-practice-findings-from-a-large-contemporaneous-real-world-cohort/)
- [Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort](/resources/publications/data/ra-bdmard-initiation-disease-activity-rwd/)
- [Treatment Patterns in Large Vessel Arteritis (Giant Cell Arteritis and Temporal Arteritis): Findings from a Large Contemporaneous Real-World Cohort in the U.S.](/resources/publications/data/large-vessel-arteritis-treatment-patterns-rwd/)
- [Age and Gender Differences in Comorbidities among Patients with Rheumatoid Arthritis in a Large US-Based Real World Cohor](/resources/publications/data/ra-age-gender-comorbidities-rwd/)
- [Patient Characteristics and Current Management of Systemic Lupus Erythematosus Patients in a Large, Representative US-Based Real World Cohort](/resources/publications/data/sle-patient-management-rwd-cohort/)
- [Improvements in Disease Activity Scores Associated with bDMARD use by Rheumatoid Arthritis Patients in a Large US-Based Real World Cohort](/resources/publications/data/ra-bdmard-use-disease-activity-improvements/)
- [Availability of Disease Activity Measures from Systemic Lupus Erythematosus Patients in a Large, Representative US-Based Real World Registry Cohort](/resources/publications/data/sle-disease-activity-measures-availability-registry/)
- [Patient Characteristics and Management Of Juvenile Idiopathic Arthritis (JIA) In a Large, Representative Real-World Cohort](/resources/publications/data/jia-patient-management-rwd-cohort/)
- [Characteristics and Disease Management in a Large Real-World Lupus Nephritis Cohort in the U.S.](/resources/publications/data/lupus-nephritis-management-rwd-cohort/)
- [Predictors of Improvement in Tender Joint Counts Among Patients with Systemic Lupus Erythematosus in A Large, Representative US-Based Real-World Registry Cohort.](/resources/publications/data/sle-predictors-tender-joint-improvement-registry/)
- [Joint Involvement and Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: Calculation of Swollen to Tender Joint Count Ratio in a Real-World Cohort in the U.S.](/resources/publications/data/sle-joint-disease-activity-rwd-cohort/)
- [Assessing Comorbid Inflammatory Arthritis Conditions and Swollen to Tender Joint Count Ratios in a Real-World Systemic Lupus Erythematosus Cohort](/resources/publications/data/sle-comorbid-arthritis-joint-count-rwd/)
- [An Evaluation of Real-World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US](/resources/publications/data/rwd-biologics-rare-systemic-vasculitides/)
- [Characterizing Patients Initiating Abaloparatide, Teriparatide, or Denosumab in a Real-World Setting: a US Linked Claims and EMR Database Analysis](/resources/publications/data/rwd-abaloparatide-teriparatide-denosumab-use/)
- [Harmonized Outcome Measures for Use in Degenerative Lumbar Spondylolisthesis Patient Registries and Clinical Practice](https://pubmed.ncbi.nlm.nih.gov/33740766/)
- [Comparison of an AI–Enabled Patient Decision Aid vs Educational Material on Decision Quality, Shared Decision-Making, Patient Experience, and Functional Outcomes in Adults with Knee Osteoarthritis: A Randomized Clinical Trial](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776550)
- [Validation of a Machine Learning Approach to Estimate Systemic Lupus Erythematosus Disease Activity Index Score Categories and Application in a Real-World Dataset](/resources/publications/ai/ml-validation-estimate-sledai-sle/)
- [Prediction of Non-Response to First-Line Methotrexate Treatment in Rheumatoid Arthritis: A Real-World Data Analysis Using Machine Learning](/resources/publications/ai/ml-predict-methotrexate-nonresponse-ra/)
- [Patient Characteristics and Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: The OM1 RA Registry](/resources/publications/data/ra-upadacitinib-outcomes-registry/)
- [Characterizing Non-Response to Methotrexate Monotherapy Among Rheumatoid Arthritis Patients in a Large Real-World Longitudinal Cohort](/resources/publications/data/ra-methotrexate-nonresponse-rwd/)
- [Validation of a Machine Learning Approach to Estimate Clinical Disease Activity Index Scores for Rheumatoid Arthritis](https://rmdopen.bmj.com/content/rmdopen/7/3/e001781.full.pdf)
- [A Cross-Sectional Study of Rheumatoid Arthritis (RA) Diagnoses in Patients with Systemic Lupus Erythematosus (SLE)](/resources/publications/data/ra-diagnosis-in-sle-patients-study/)
- [Effect of Patient Reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice](/resources/publications/data/ra-pros-dmard-therapy-changes-rwd-effect/)
- [Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice](/resources/publications/data/nr-axspa-disease-burden-clinical-practice/)
- [Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Rheumatoid Arthritis Patients](/resources/publications/data/ra-biologic-change-disease-activity-rwd/)
- [Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients](/resources/publications/data/psa-biologic-change-disease-activity-rwd/)
- [Machine Learning Models to Estimate Disease Activity Measures in Real-World Data Sources: Lessons Learned from Four Autoimmune Diseases](/resources/publications/ai/ml-disease-activity-4-autoimmune-rwd/)
- [Lessons Learned from the Development of Machine Learning Models to Estimate Validated Measures of Disease Activity and Symptom Severity Using Real-World Data for Four Chronic Conditions](/resources/publications/ai/ml-estimate-disease-activity-rwd-4-conditions/)
- [Disease Activity in Rheumatoid Arthritis Patients Initiating Anti-Obesity Medication in a Longitudinal US-Based Real-World Cohort](/resources/publications/data/ra-anti-obesity-med-rwd-cohort/)
- [Predictors of Low Disease Activity/ Remission Amongst Rheumatoid Arthritis Patients Experiencing Inadequate Response to Biologic/ Targeted Synthetic Disease-Modifying Antirheumatic Drugs](/resources/publications/data/ra-predictors-low-disease-activity-biologics/)
- [Registries for Evaluating Patient Outcomes: A User’s Guide, 3rd Edition](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/registries-guide-3rd-edition_research.pdf)
- [Managing Missing Patient Data in Registries: Addendum to Registries for Evaluating Patient Outcomes, 3rd Edition.](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/missing-data-registries-guide-3rd-ed-addendum-white-paper.pdf)
- [Biorepositories: Addendum to Registries for Evaluating Patient Outcomes, 3rd Edition.](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/biorepositories-registries-guide-3rd-ed-addendum-white-paper.pdf)
- [Registries for Evaluating Patient Outcomes: A User’s Guide, 4th Edition](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/registries-evaluating-patient-outcomes-4th-edition.pdf)
- [Mammographic Screening in Routine Practice: Multisite Study of Digital Breast Tomosynthesis and Digital Mammography Screenings](https://pubs.rsna.org/doi/epdf/10.1148/radiol.221571)
- [OM1’s Data Automation in Prospective Studies and Registries.](/resources/whitepapers/registries/data-automation-prospective-studies/)
- [Heart Failure eBook](https://om1.turtl.co/story/heartfailure1/)
- [Device eBook](https://om1.turtl.co/story/device1/page/1)
- [PhenOM eBook](https://om1.turtl.co/story/phenom1/page/1)
- [Aspen eBook](https://om1.turtl.co/story/aspen1/)
- [Rheumatology ebook](https://om1.turtl.co/story/rheumatology-ebook/page/1)
- [Derm eBook](https://om1.turtl.co/story/dermatology1/)
- [Neuro eBook](https://om1.turtl.co/story/neuro1/)
- [RWA eBook](https://om1.turtl.co/story/rwa1/)
- [Lupus eBook](https://om1.turtl.co/story/lupus-ebook1/)
- [MS Insights eBook](https://om1.turtl.co/story/ms-insights2/)
- [PsO Insights eBook](https://om1.turtl.co/story/pso-insights1/)
- [Mental Health eBook](https://om1.turtl.co/story/mentalhealth1/)
- [Immunology eBook](https://om1.turtl.co/story/immunology1/)
- [2024 Year in Review](https://om1.turtl.co/story/2024-in-review/page/1)
- [From Promise to Reality: How AI Is Transforming Registries for Post-Approval Evidence Generation](https://www.fiercebiotech.com/premium/webinar/1373775?pk=OM1-WB-1113025-OM1)
- [Redefining Evidence Generation: Innovative AI-Enabled Approaches for a New Era of Therapies](https://medicalaffairs.org/webinars-redefining-evidence-generation/)
- [Powering Long-Term Evidence Generation in Rare Dermatologic Disease](/resources/case-studies/other/powering-long-term-evidence-generation-in-rare-dermatologic-disease/)
- [Behind the Insights: Ep 06 FDA Draft Guidance on Post-Approval Data for Cell & Gene Therapies](https://youtu.be/cuVnCryjIE0)
- [Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis](/resources/publications/other/effectiveness-of-new-initiators-of-tofacitinib-and-other-biologic-targeted/)
- [From Subtyping to Measuring and Predicting Outcomes: How AI is Changing Rheumatology and Immunology Research](https://www.youtube.com/watch?v=ukEK6dP4ObE)
- [Disease Severity at Advanced Therapy Initiation in Real-World Psoriasis Patients in the U.S](/resources/publications/other/disease-severity-at-advanced-therapy-initiation-in-real-world-psoriasis/)
- [Understanding Remission: Predictors of Low Disease Activity in Rheumatoid Arthritis Patients Experiencing Inadequate Response to b/tsDMARDS](/resources/blogs/other/understanding-remission-predictors-of-low-disease-activity-in-rheumatoid-arthritis-patients-experiencing-inadequate-response-to-btsdmards/)
- [OM1 Rheumatoid Arthritis Dataset Rated High Quality as Cornerstone AI Partnership Speeds Future Quality Reviews](https://www.businesswire.com/news/home/20250821833445/en/OM1-Rheumatoid-Arthritis-Dataset-Rated-High-Quality-as-Cornerstone-AI-Partnership-Speeds-Future-Quality-Reviews)
- [OM1 expands neurology network to over 3 million patients for real-world data research](https://becarispublishing.com/digital-content/blog-post/om1-expands-neurology-network-over-3-million-patients-real-world-data-research)
- [OM1 Adds a Half Million Patients to Neurology Network, Strengthening Real-World Evidence Generation and Accelerating Innovation in Neurology](https://www.businesswire.com/news/home/20250812898616/en/OM1-Adds-a-Half-Million-Patients-to-Neurology-Network-Strengthening-Real-World-Evidence-Generation-and-Accelerating-Innovation-in-Neurology)
- [OM1 Appoints Hunter Lane as Chief Product Officer](https://www.businesswire.com/news/home/20250805127955/en/OM1-Appoints-Hunter-Lane-as-Chief-Product-Officer)
- [Behind the Insights: Ep 05 Rheumatoid Arthritis Remission with Chandra Gopalakrishnan, MD, MPH](https://youtu.be/8Md10Fj7KRo)
- [Understanding Depression Subtypes and Burden Through Linked Real-World Data](https://link.springer.com/article/10.1186/s12888-025-07139-x)
- [OM1’s Data Automation in Prospective Studies and Registries](/resources/whitepapers/registries/om1s-data-automation-in-prospective-studies-and-registries/)
- [Predicting Response and Personalizing Treatment Decisions in Mental Health: New Opportunities with AI and Real-World Data](https://www.fiercepharma.com/premium/webinar/1370286?pk=OM1-wb-062625-OM1)
- [Behind the Insights: Ep 04 GLP-1s & Suicidal Ideation, Jessica Probst, MPH & Carl Marci, MD](https://youtu.be/_VVbbFhxQpU)
- [Understanding the link between GLP-1 therapies and suicidal ideation using real-world data](https://becarispublishing.com/digital-content/blog-post/understanding-link-between-glp1-therapies-and-suicidal-ideation-using-real-world-data)
- [OM1’s PhenOM® Foundation AI Surpasses One Billion Years of Health History in Model Training](https://www.businesswire.com/news/home/20250513955918/en/OM1s-PhenOM-Foundation-AI-Surpasses-One-Billion-Years-of-Health-History-in-Model-Training)
- [Rethinking Evidence: Leveraging Real-World Data to Accelerate Drug Development](https://go.diaglobal.org/OM1-Leveraging-Real-World-Data-to-Accelerate-Drug-Development.html)
- [OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025](https://www.morningstar.com/news/business-wire/20250508081553/om1-to-present-groundbreaking-research-on-glp-1-agonists-and-suicidal-ideation-at-ispor-2025)
- [OM1 to Present Groundbreaking Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025.](https://www.morningstar.com/news/business-wire/20250508081553/om1-to-present-groundbreaking-research-on-glp-1-agonists-and-suicidal-ideation-at-ispor-2025)
- [Patient Characteristics, Disease Symptoms, and Treatment Patterns of Patients With Ulcerative Colitis and Crohn’s Disease From the United States: Results From a Retrospective, Longitudinal Cohort Study](/resources/publications/other/patient-characteristics-uc-cd/)
- [OM1 expands mental health network to over six million patients, enhancing real-world evidence and personalized care capabilities](https://becarispublishing.com/digital-content/blog-post/om1-expands-mental-health-network-over-six-million-patients-enhancing-real-world)
- [OM1 Adds 1 Million Patients to Its Mental Health Network, Significantly Expanding Specialty Coverage and Driving New Possibilities for Real-World Research and Personalized Care](https://www.businesswire.com/news/home/20250422262553/en/OM1-Adds-1-Million-Patients-to-Its-Mental-Health-Network-Significantly-Expanding-Specialty-Coverage-and-Driving-New-Possibilities-for-Real-World-Research-and-Personalized-Care)
- [Behind the Insights: Ep 03 Decoding Treatment-Resistant Depression with Carl Marci, MD](https://youtu.be/gvhant8TSSQ)
- [OM1 expands into Europe to enhance AI-driven real-world evidence solutions](https://becarispublishing.com/digital-content/blog-post/om1-expands-into-europe-enhance-ai-driven-real-world-evidence-solutions)
- [Behind the Insights: Ep 02 The Next Era of Evidence Generation with Rich Gliklich, MD](https://youtu.be/ZCzdXDKWxDE)
- [OM1 Expands into Europe to Strengthen Support for Life Sciences with AI-Driven Real-World Evidence Solutions](https://www.businesswire.com/news/home/20250312318676/en/OM1-Expands-into-Europe-to-Strengthen-Support-for-Life-Sciences-with-AI-Driven-Real-World-Evidence-Solutions)
- [Behind the Insights: Ep 01 AI in Dermatology Real-World Data with Joseph Zabinski, PhD, MEM](https://youtu.be/paGyqrMQZT0)
- [Transforming Cancer Detection: The Power of Real-World Evidence and AI in Multi-Cancer Early Detection (MCED) Studies](https://medicalaffairs.org/ondemand-jan1025/)
- [Nalu PNS System Significantly Reduces Healthcare-Related Costs in Chronic Pain Patients](https://www.businesswire.com/news/home/20250108411036/en/Nalu-PNS-System-Significantly-Reduces-Healthcare-Related-Costs-in-Chronic-Pain-Patients)
- [Transform Your Patient Insights with AI-Enhanced Real-World Data](https://youtu.be/o3hMwzd_mQg)
- [American Academy of Dermatology launches innovative project to improve outcomes for patients with hidradenitis suppurativa](https://www.aad.org/news/improve-outcomes-hidradenitis-suppurativa)
- [MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?](https://www.pharmexec.com/view/mdma-therapy-mental-health-conditions-benefits-outweigh-risks)
- [Joseph Zabinski Of OM1: How AI Is Disrupting Our Industry, and What We Can Do About It](https://medium.com/authority-magazine/joseph-zabinski-of-om1-how-ai-is-disrupting-our-industry-and-what-we-can-do-about-it-e5520f924b97)
- [AI and Real-World Evidence: Transforming Pharmaceutical Research and Market Access](https://marketaccesstoday.com/ai-and-real-world-evidence-transforming-pharmaceutical-research-and-market-access/?doing_wp_cron=1728306864.5373640060424804687500)
- [Q&A: New Alzheimer’s dataset allows ‘whispers from the brain’ to assist in early detection](https://www.healio.com/news/neurology/20241002/qa-new-alzheimers-dataset-allows-whispers-from-the-brain-to-assist-in-early-detection)
- [Driving Point-of-care Decisions With RWE](https://www.appliedclinicaltrialsonline.com/view/point-of-care-decisions-rwe)
- [The Potential of AI in Data Collection](https://www.appliedclinicaltrialsonline.com/view/ai-data-collection)
- [People are using ChatGPT as a therapist. Mental health experts have some concerns](https://www.fastcompany.com/91198644/people-are-using-chatgpt-as-a-therapist-mental-health-experts-have-some-concerns)
- [Regulatory Concerns Associated With Utilizing RWD](https://www.appliedclinicaltrialsonline.com/view/regulatory-concerns-rwd)
- [Reducing Burden With RWD](https://www.appliedclinicaltrialsonline.com/view/reducing-burden-rwd)
- [The Importance of RWD in Rare Disease Research](https://www.appliedclinicaltrialsonline.com/view/importance-rwd-rare-disease-research)
- [Completing the patient journey: using AI and RWD to see the unseen](https://youtu.be/GkJ0B8OC1UY)
- [OM1 Earns Frost & Sullivan's 2024 North American New Product Innovation Award for Transforming Real-world Evidence Analytics Solutions Industry with Its Pioneering AI-powered Platforms](https://www.prnewswire.com/news-releases/om1-earns-frost--sullivans-2024-north-american-new-product-innovation-award-for-transforming-real-world-evidence-analytics-solutions-industry-with-its-pioneering-ai-powered-platforms-302249870.html?tc=eml_cleartime)
- [Revolutionizing Prospective Studies and Registries with Automation and AI](https://youtu.be/97L_v0eMakQ)
- [2024 New Product Innovator](/resources/news-and-articles/ai/2024-new-product-innovator/)
- [OM1 Appoints Catherine Richards as President](https://www.businesswire.com/news/home/20240819406641/en/OM1-Appoints-Catherine-Richards-as-President)
- [Unveiling the Unseen: AI's Role in Identifying Treatment-Resistant Depression](https://www.youtube.com/watch?v=NgnzU_eSFLo)
- [AI on the GPP case](https://www.aadmeetingnews.org/2024-aad-innovation-academy/article/22916810/ai-on-the-gpp-case)
- [OM1 Contributes to Alzheimer’s Disease Research With New PremiOM Dataset of Over 1 Million Patients](https://www.businesswire.com/news/home/20240730327077/en/OM1-Contributes-to-Alzheimer%E2%80%99s-Disease-Research-With-New-PremiOM-Dataset-of-Over-1-Million-Patients)
- [How good is AI at diagnosing patients? Better than you’d think](https://www.modernhealthcare.com/digital-health/ai-diagnostics-accuracy-dementia-alzheimers-cancer)
- [How can Life Science Technology Providers Support the Pharmaceutical Industry in the Transition Toward More Digitally Connected Operations?](https://www.pharmasalmanac.com/articles/how-can-life-science-technology-providers-support-the-pharmaceutical-industry)
- [Panalgo and OM1 Expand Partnership to Offer OM1's PremiOM Datasets in Panalgo's IHD Analytics Platform](https://www.prweb.com/releases/panalgo-and-om1-expand-partnership-to-offer-om1s-premiom-datasets-in-panalgos-ihd-analytics-platform-302176499.html)
- [OM1, a Pioneer in Patient Registries, Launches Registries Center of Excellence](http://www.mobilehealthtimes.com/om1-a-pioneer-in-patient-registries-launches-registries-center-of-excellence/)
- [OM1, a Pioneer in Patient Registries, Launches Its Registries Center of Excellence](https://www.businesswire.com/news/home/20240613534316/en/OM1-a-Pioneer-in-Patient-Registries-Launches-Its-Registries-Center-of-Excellence)
- [AI in Healthcare – Enhancing Treatment Plans, Engaging Patients, and Impacting Patient Outcomes](https://www.healthcareittoday.com/2024/06/10/ai-in-healthcare-enhancing-treatment-plans-engaging-patients-and-impacting-patient-outcomes/)
- [Joseph Zabinski, PhD, MEM: Navigating the Future of AI in Skin Cancer Detection](https://www.dermatologytimes.com/view/joseph-zabinski-phd-mem-navigating-the-future-of-ai-in-skin-cancer-detection)
- [Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping](https://healtheconomics.com/webinar/practical-ai-adding-insight-to-the-patient-journey-with-digital-phenotyping/?utm_bmcr_source=OMweb)
- [OM1 Unveils AI-Powered Phenotyping Platform for Personalized Medicine](https://hitconsultant.net/2024/05/06/om1-unveils-ai-powered-phenotyping-platform-for-personalized-medicine/)
- [OM1 Launches Three New Products Powered by Patented AI Platform to Expedite Delivery of Personalized Medicine](https://www.businesswire.com/news/home/20240506142990/en/OM1-Launches-Three-New-Product%5B%E2%80%A6%5D-AI-Platform-to-Expedite-Delivery-of-Personalized-Medicine)
- [Lean Digital: How AI Drives Treatment Recommendations for Weight Loss](https://www.healthcareittoday.com/2024/04/30/lean-digital-how-ai-drives-treatment-recommendations-for-weight-loss/)
- [How AI-Powered Phenotyping Enhances the Patient Journey for Life Science Applications](https://healtheconomics.com/podcast/how-ai-powered-phenotyping-enhances-the-patient-journey-for-life-science-applications/)
- [Predictions for AI in mental health in the coming year](https://pharmaphorum.com/digital/predictions-ai-mental-health-coming-year)
- [Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care](https://www.managedhealthcareexecutive.com/view/joseph-zabinski-advocates-for-patient-trust-in-ai-adoption-in-dermatology-care)
- [OM1 and Medtronic Partner on Propel Study to Assess Long-term Outcomes for Patients With Chronic Rhinosinusitis](https://www.businesswire.com/news/home/20240409797551/en/OM1-and-Medtronic-Partner-on-Propel-Study-to-Assess-Long-term-Outcomes-for-Patients-With-Chronic-Rhinosinusitis)
- [Integrated Evidence Generation: Exploring Registries in the Era of Automation](https://youtu.be/WKyP1rQK2ew)
- [Dr Joseph Zabinski Discusses Using Artificial Intelligence to Identify Patients With GPP](https://www.ajmc.com/view/dr-joseph-zabinski-discusses-using-artificial-intelligence-to-identify-patients-with-gpp)
- [How is Artificial Intelligence Growing Up?](https://www.dermatologytimes.com/view/how-is-artificial-intelligence-growing-up-)
- [Integrating Ambient Clinical Voice Technology – The Impacts, Challenges, and Benefits](https://www.healthcareittoday.com/2024/03/08/integrating-ambient-clinical-voice-technology-the-impacts-challenges-and-benefits/)
- [What strategies are being employed to accelerate product development and commercialization without compromising quality?](https://www.pharmasalmanac.com/articles/what-strategies-are-being-employed-to-accelerate-product-development-and-commercialization-without-compromising-quality)
- [Machine Learning Model Enhances Real-World Studies for Predicting Disability Progression in Multiple Sclerosis](https://www.neurologylive.com/view/machine-learning-model-enhances-real-world-studies-predicting-disability-progression-ms)
- [Promise of AI in MS Research and Treatment Showcased at ACTRIMS 2024](https://www.ajmc.com/view/promise-of-ai-in-ms-research-and-treatment-showcased-at-actrims-2024)
- [Machine learning model could assist in treatment of MS](https://www.healio.com/news/neurology/20240301/machine-learning-model-could-assist-in-treatment-of-ms)
- [Navigating Rare Dermatologic Diseases Using Artificial Intelligence](https://www.dermatologytimes.com/view/navigating-rare-dermatologic-diseases-using-artificial-intelligence)
- [Revolutionizing GPP Recognition Through Data Collection](https://www.dermatologytimes.com/view/revolutionizing-gpp-recognition-through-data-collection)
- [What Health IT Trend Has You Most Excited?](https://www.healthcareittoday.com/2024/02/28/what-health-it-trend-has-you-most-excited/)
- [OM1 to Present Research on Multiple Sclerosis at ACTRIMS Forum 2024](https://www.businesswire.com/news/home/20240227035440/en/OM1-to-Present-Research-on-Multiple-Sclerosis-at-ACTRIMS-Forum-2024)
- [Rare Disease Detection With AI: What Tools to Trust (stand alone feature)](https://www.dermatologytimes.com/view/rare-disease-detection-with-ai-what-tools-to-trust)
- [Enhancing Your Toolbox to Improve Patient Care](https://www.dermatologytimes.com/view/enhancing-your-toolbox-to-improve-patient-care)
- [Balancing Innovation and Digital Transformation with Regulatory Compliance and Patient Safety](https://www.healthcareittoday.com/2024/02/02/balancing-innovation-and-digital-transformation-with-regulatory-compliance-and-patient-safety/)
- [AI and Digital Phenotyping for Clinical Development](https://youtu.be/w4KnniQE60A)
- [AI Identifies Clinical Phenotypes of Rapid Fibrosis Progression in MASH](https://www.gastroenterologyadvisor.com/metabolic-liver-disease/artificial-intelligence-identifies-phenotypes-of-rapid-fibrosis-progression-in-mash/)
- [Healthcare AI – 2024 Health IT Predictions](https://www.healthcareittoday.com/2024/01/19/healthcare-ai-2024-health-it-predictions/)
- [Uses of AI in Healthcare – 2024 Health IT Predictions](https://www.healthcareittoday.com/2024/01/17/uses-of-ai-in-healthcare-2024-health-it-predictions/)
- [Cautionary Views of Healthcare AI – 2024 Health IT Predictions](https://www.healthcareittoday.com/2024/01/15/cautionary-views-of-healthcare-ai-2024-health-it-predictions/)
- [Value Based Care – 2024 Health IT Predictions](https://www.healthcareittoday.com/2024/01/05/value-based-care-2024-health-it-predictions/)
- [Health technology in 2024: Projections for AI, digital health, and more](https://www.chiefhealthcareexecutive.com/view/health-technology-in-2024-projections-for-ai-digital-health-and-more)
- [A cancer battle, AI, and starting healthcare companies: Our top podcasts of 2023](https://www.chiefhealthcareexecutive.com/view/a-cancer-battle-ai-and-starting-healthcare-companies-our-top-podcasts-of-2023)
- [Population Health, Access, and Equity in 2024](https://www.healthitanswers.net/population-health-access-and-equity-in-2024/)
- [Will AI Continue to Demand All the Attention in 2024?](https://www.healthitanswers.net/will-ai-continue-to-demand-all-the-attention-in-2024/)
- [New Treatments Bring Hope for Autoimmune Skin Conditions](https://www.dermatologytimes.com/view/new-treatments-bring-hope-for-autoimmune-skin-conditions)
- [What Do You See As The Most Significant Regulatory Decision Or Guidance On The Horizon For 2024 (Or Beyond)?](https://www.pharmasalmanac.com/articles/what-do-you-see-as-the-most-significant-regulatory-decision-or-guidance-on-the-horizon-for-2024-or-beyond)
- [What Do You Think Was The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023?](https://www.pharmasalmanac.com/articles/what-do-you-think-was-the-single-most-consequential-event-or-result-in-pharma/biopharma-in-2023)
- [Shifting the Paradigm to Pragmatic Evidence Generation](https://healtheconomics.com/shifting-the-paradigm-to-pragmatic-evidence-generation/)
- [How AI Can Help Dermatology: Diagnosis, Treatment, Risk, and R&D](https://healtheconomics.com/podcast/how-ai-can-help-dermatology-diagnosis-treatment-risk-and-rd/)
- [A new era of integrated evidence generation: Deep dive into OM1 case study spotlight from the DIA Real-World Evidence Conference 2023](https://www.evidencebaseonline.com/a-new-era-of-integrated-evidence-generation-deep-dive-into-om1-case-study-spotlight-from-the-dia-real-world-evidence-conference-2023/)
- [Women in Science: Kathryn Starzyk on the power and complexities of real-world evidence](https://www.biopharma-reporter.com/Article/2023/11/01/women-in-science-kathryn-starzyk-on-the-power-and-complexities-of-rwe)
- [Aspects of Social Determinants of Health: Acting on SDoH](https://www.healthcareittoday.com/2023/10/19/aspects-of-social-determinants-of-health-acting-on-sdoh/)
- [Dr Carl Marci talks real-world data, early detection of Parkinson’s and how personalized intervention is key to quality of life.](https://longevity.technology/news/personalized-medicine-is-the-future-and-ai-combined-with-data-is-the-key-to-bringing-it-to-market/)
- [Aspects of Social Determinants of Health: Collecting Data](https://www.healthcareittoday.com/2023/10/18/aspects-of-social-determinants-of-health-collecting-data/)
- [Aspects of Social Determinants of Health: An Introduction](https://www.healthcareittoday.com/2023/10/16/aspects-of-social-determinants-of-health-an-introduction/)
- [2023 Fierce Healthcare Innovation Awards Finalists](https://fiercehealthcareinnovationawards.fiercelifesciences.com/fiercehealthcareinnova/2023-finalists)
- [OM1 Launches Asthma and Chronic Rhinosinusitis Datasets to Expand RWE](https://hitconsultant.net/2023/10/02/om1-launches-asthma-and-chronic-rhinosinusitis-datasets/)
- [Stefan Weiss, MD, Discusses OM1’s New HS Dataset and Expanded Dermatology Network](https://www.dermatologytimes.com/view/stefan-weiss-md-discusses-om1-s-new-hs-dataset-and-expanded-dermatology-network)
- [Artificial Intelligence: Friend or Foe?](https://www.dermatologytimes.com/view/artificial-intelligence-friend-or-foe-)
- [OM1 Launches Asthma and Chronic Rhinosinusitis Datasets to Expand Real-World Evidence in Respiratory and ENT](https://www.businesswire.com/news/home/20231002821634/en/OM1-Launches-Asthma-and-Chronic-Rhinosinusitis-Datasets-to-Expand-Real-World-Evidence-in-Respiratory-and-ENT)
- [OM1 Launches HS Dataset to Expand Use of Real-World Evidence in Dermatology](https://practicaldermatology.com/news/om1-launches-hs-dataset-to-expand-real-world-evidence-in-dermatology?c4src=news:featured)
- [OM1 Launches Hidradenitis Suppurativa Dataset to Expand Real-World Evidence in Dermatology](https://www.businesswire.com/news/home/20230921621716/en/OM1-Launches-Hidradenitis-Suppurativa-Dataset-to-Expand-Real-World-Evidence-in-Dermatology?utm_content=265126434)
- [The Sooner, the Better: Detecting and Decoding Alzheimer’s with Real-World Data](https://healtheconomics.com/podcast/the-sooner-the-better-detecting-and-decoding-alzheimers-with-real-world-data/)
- [Using RWD and Clinical Narratives to Generate Commercial Insights](https://www.mmm-online.com/home/channel/sponsored/using-rwd-and-clinical-narratives-to-generate-commercial-insights-on-discontinuation-treatment-and-prescribing-patterns/?utm_source=marketing&utm_medium=social&utm_campaign=OM1)
- [OM1 Appoints Shawn Bates as Chief Commercial Officer](https://www.businesswire.com/news/home/20230919400545/en/OM1-Appoints-Shawn-Bates-as-Chief-Commercial-Officer?_gl=1*1mts7r9*_ga*MTg2MzgzMzY5My4xNjkzNTAxMTI4*_ga_ZQWF70T3FK*MTY5NTEyODU5Mi4yMi4xLjE2OTUxMjg2MDMuNDkuMC4w)
- [The 2023 PharmaVoice 100: Carl Marci, MD](https://www.pharmavoice.com/news/pharmavoice100-pv100-pharma-leaders/690951/)
- [Reclaiming registries for integrated evidence generation throughout the product life cycle](https://www.biopharmadive.com/spons/reclaiming-registries-for-integrated-evidence-generation-throughout-the-pro/692902/)
- [What Piece of Conventional Industry Wisdom Do You Think is Misguided, Outdated, or Just Plain Wrong?](https://www.pharmasalmanac.com/articles/what-piece-of-conventional-industry-wisdom-do-you-think-is-misguided-outdated-or-just-plain-wrong)
- [How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?](https://www.pharmasalmanac.com/articles/how-is-your-organization-currently-leveraging-real-world-data/evidence-and-what-uses-do-you-anticipate-in-the-future?utm_content=264674217&utm_medium=social&utm_source=linkedin&hss_channel=lcp-15179693)
- [Healthcare Innovation Presents - 40 Under 40 - Your 2023 Class](https://www.hcinnovationgroup.com/leadership-professional-development/article/53070382/40-under-40)
- [OM1 Launches Parkinson’s Disease Premium Dataset to Expand Real-World Evidence in Neuroscience](https://www.businesswire.com/news/home/20230907179624/en/OM1-Launches-Parkinson%E2%80%99s-Disease-Premium-Dataset-to-Expand-Real-World-Evidence-in-Neuroscience)
- [EXPERT PRAISES PROPOSED FEDERAL RULE TO STRENGTHEN BEHAVIORAL HEALTH PARITY](https://www.healthleadersmedia.com/clinical-care/expert-praises-proposed-federal-rule-strengthen-behavioral-health-parity)
- [Leveraging Real-World Data for Precision Obesity Treatment](https://healtheconomics.com/leveraging-real-world-data-for-precision-obesity-treatment/)
- [Q1. In what areas of pharma/biopharma are you most excited to see increased adoption of artificial intelligence (AI) and machine learning?](https://www.pharmasalmanac.com/articles/what-is-your-plan-to-build-a-more-sustainable-business-practice-in-the-coming-years-0)
- [12 New Ways Companies Are Helping to Improve Adherence](https://www.pm360online.com/12-new-ways-companies-are-helping-to-improve-adherence/?GTTabs=6)
- [OM1 to Expedite and Improve Research With New Study Automation Platform & Evidence Generation Solution](https://www.businesswire.com/news/home/20230626346071/en/OM1-to-Expedite-and-Improve-Research-With-New-Study-Automation-Platform-Evidence-Generation-Solution)
- [Walgreens, Freenome Team Up, New AI Products from ObjectiveHealth, Saama, More](https://www.clinicalresearchnewsonline.com/news/2023/06/29/walgreens-freenome-team-up-new-ai-products-from-objectivehealth-saama-more)
- [American Academy of Dermatology launches innovative project to improve outcomes for patients with life-threatening pustular psoriasis](https://www.newswise.com/articles/american-academy-of-dermatology-launches-innovative-project-to-improve-outcomes-for-patients-with-life-threatening-pustular-psoriasis)
- [Patti’s People – Patti Peeples speaks with Rich Gliklich](https://www.evidencebaseonline.com/videos/pattis-people-patti-peeples-speaks-with-rich-gliklich/)
- [Machine learning model accurately estimates PHQ-9 scores from clinical notes](https://www.healio.com/news/psychiatry/20230609/machine-learning-model-accurately-estimates-phq9-scores-from-clinical-notes)
- [Empowering unprecedented real-world analyses of breast cancer screening outcomes](/resources/case-studies/registries/empowering-unprecedented-real-world-analyses-of-breast-cancer-screening-outcomes/)
- [Understanding How Data Analytics Help Improve Health Outcomes With Stefan Weiss, MD](https://www.dermatologytimes.com/view/understanding-how-data-analytics-help-improve-health-outcomes-with-stefan-weiss-md)
- [“I Know It When I See It”: Definitions of Treatment-Resistant Depression](https://www.psychiatrictimes.com/view/i-know-it-when-i-see-it-definitions-of-treatment-resistant-depression)
- [How Real-World Data Can Contribute to Improved Mental Health Treatment](https://www.pm360online.com/how-real-world-data-can-contribute-to-improved-mental-health-treatment/)
- [OM1 Launches Analytics to Deliver Mental Health & Immunology Insights on Prescriber Trends and Therapy Effectiveness](https://www.businesswire.com/news/home/20230524005177/en/OM1-Launches-Analytics-to-Deliver-Mental-Health-Immunology-Insights-on-Prescriber-Trends-and-Therapy-Effectiveness)
- [Defining Treatment-Resistant Depression](https://www.psychiatrictimes.com/view/defining-treatment-resistant-depression)
- [Peek Behind the Poster: Machine learning to estimate disease activity measures for autoimmune diseases in real-world data sources](https://www.evidencebaseonline.com/peek-behind-the-poster-machine-learning-to-estimate-disease-activity-measures-for-autoimmune-diseases-in-real-world-data-sources/)
- [Various Definitions of Treatment Resistant Depression](https://www.psychiatrictimes.com/view/various-definitions-of-treatment-resistant-depression)
- [Health Equity: Searching for a New Angle](https://www.healthcareittoday.com/2023/05/10/health-equity-searching-for-a-new-angle/)
- [New mammography guidance throws another twist into screening debate](https://www.axios.com/2023/05/10/new-mammography-guidance-screening-debate)
- [Amplifying lupus disease activity with real-world data and machine learning](https://www.biopharmadive.com/spons/amplifying-lupus-disease-activity-with-real-world-data-and-machine-learning/649101/)
- [DataDerm Update](https://assets.bmctoday.net/practicaldermatology/pdfs/PD0423_digital%20practice.pdf)
- [Using Artificial Intelligence to Get the Right Drug to the Right Patient at the Right Time](https://www.pharmasalmanac.com/articles/using-artificial-intelligence-to-get-the-right-drug-to-the-right-patient-at-the-right-time)
- [Large-Scale Comparative Study for Cancer Screening for Label Expansion](/resources/case-studies/registries/large-scale-comparative-study-for-cancer-screening-for-label-expansion/)
- [As suicide rates spike, new AI platform could ‘fill the gap’ in mental health care, say Boston researchers](https://www.foxnews.com/health/suicide-rates-spike-ai-platform-could-fill-gap-mental-health-care-boston-researchers)
- [Data Book podcast: Joe Zabinski of OM1 talks about AI and ChatGPT](https://www.chiefhealthcareexecutive.com/view/data-book-podcast-joe-zabinski-of-om1-talks-about-ai-and-chatgpt)
- [OM1 Unveils Patented, AI-powered Platform to Accelerate Personalized Medicine](https://www.businesswire.com/news/home/20230413005032/en/OM1-Unveils-Patented-AI-powered-Platform-to-Accelerate-Personalized-Medicine?_gl=1*i9dlbc*_ga*NDA5NTMxMDI1LjE2ODEyMTc3ODI.*_ga_ZQWF70T3FK*MTY4MTM5MDg0NC4xMS4xLjE2ODEzOTA5MTUuNTIuMC4w)
- [Metamorphosis of Women in Health Tech](/resources/blogs/other/metamorphosis-of-women-in-health-tech/)
- [Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care](https://www.ajmc.com/view/dermatology-data-can-direct-policy-priorities-but-gaps-reflect-inequities-of-care)
- [RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity](https://www.dermatologytimes.com/view/rapid3-scores-may-help-determine-the-impact-of-dmard-therapy-on-psa-severity)
- [Clinical investigators need to be wary of confounding and bias in real-world studies; here is what to look for and how to address it](https://www.labpulse.com/research-and-development/clinical-trial/article/15352700/investigators-need-to-be-way-of-confounding-and-bias-in-realworld-studies-here-is-what-to-look-for-and-how-to-address-it)
- [Biden's 'Cancer Moonshot' is already being fueled by tech addressing breast cancer](https://www.fiercehealthcare.com/health-tech/bidens-cancer-moonshot-already-being-fueled-tech-addressing-breast-cancer)
- [Hard to Define, Harder to Find Patients: Using AI & Real-World Data to Understand Treatment Resistant Depression](https://healtheconomics.com/hard-to-define-harder-to-find-patients-using-ai-real-world-data-to-understand-treatment-resistant-depression/)
- [AI Uncovers Other Patients Like You to Support Doctors](https://www.healthcareittoday.com/2023/03/02/ai-uncovers-other-patients-like-you-to-support-doctors/)
- [OM1 Expands Mental Health Offering With Real-World Datasets Including Schizophrenia and Bipolar Disorder](https://www.businesswire.com/news/home/20230302005039/en/OM1-Expands-Mental-Health-Offering-With-Real-World-Datasets-Including-Schizophrenia-and-Bipolar-Disorde)
- [OM1 Launches Analytic Reports Uncovering Causes of Medication Discontinuation in Immunology Patients](https://www.businesswire.com/news/home/20230202005071/en/OM1-Launches-Analytic-Reports-Uncovering-Causes-of-Medication-Discontinuation-in-Immunology-Patients)
- [What do you view as the most disruptive or transformational technology or development on the horizon?](https://www.pharmasalmanac.com/articles/q1-what-do-you-view-as-the-most-disruptive-or-transformational-technology-or-development-on-the-horizon)
- [Kazuki Yoshida, MD, MPH, ScD: Methotrexate Access in the Post-Roe v Wade Era](https://www.rheumatologynetwork.com/view/kazuki-yoshida-md-mph-scd-methotrexate-access-in-the-post-roe-v-wade-era)
- [OM1 Aims To Improve Healthcare Outcomes Through Big Data And AI](https://www.forbes.com/sites/brucerogers/2022/11/22/om1-aims-to-improve-healthcare-outcomes-through-big-data-and-ai/?sh=65cf35c17f50)
- [Many Female Arthritis Drug Users Face Restrictions After Dobbs](https://news.bloomberglaw.com/health-law-and-business/many-female-arthritis-drug-users-face-restrictions-after-dobbs)
- [Personalizing Medicine: AI and RWE in the Medtech Context](https://themedtechconference.com/personalizing-medicine/)
- [How’d They Do It? Tech Leaders Reflect on How They Innovated To Solve Health Problems](https://builtin.com/brand-studio/solving-innovative-health-problems)
- [Using Real-World Data for Patients with Multiple Sclerosis: A New Machine Learning Model for the Expanded Disability Status Scale (EDSS)](https://healtheconomics.com/using-real-world-data-for-patients-with-multiple-sclerosis-a-new-machine-learning-model-for-the-expanded-disability-status-scale-edss/)
- [AI Applications for Clinical Development: From Identifying Patients to Amplifying Trial Endpoints](https://editions.mydigitalpublication.com/publication/?m=67409&i=756524&p=43&ver=html5)
- [OM1 LAUNCHES A NEW ESTIMATION MODEL FOR THE EXPANDED DISABILITY STATUS SCORE (EDSS) FOR MULTIPLE SCLEROSIS PATIENTS](https://www.prnewswire.com/news-releases/om1-launches-a-new-estimation-model-for-the-expanded-disability-status-score-edss-for-multiple-sclerosis-patients-301574449.html?tc=eml_cleartime)
- [Validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis](https://journals.sagepub.com/doi/10.1177/20552173221108635)
- [Real-world data: A health equity lens for research](https://www.biopharmadive.com/spons/real-world-data-a-health-equity-lens-for-research/624983/)
- [Understanding Heart Failure through the Real-World Data Lens](https://www.pharmexec.com/view/understanding-heart-failure-through-the-real-world-data-lens?utm_source=sfmc&utm_medium=linkedin&utm_campaign=mktg_brandinsights)
- [A new approach for post-marketing safety studies](https://www.biopharmadive.com/spons/a-new-approach-for-post-marketing-safety-studies/620838/)
- [Real-World Data Delivers Dose of Hope for Mental Health in the U.S.](https://www.pharmexec.com/view/real-world-data-delivers-dose-of-hope-for-mental-health-in-the-u-s-)
- [Real-World Data & AI: Bridging the Gap from Population to Personalization](https://www.insideprecisionmedicine.com/news-and-features/real-world-data-ai-bridging-the-gap-from-population-to-personalization/)
- [A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm](/resources/publications/other/a-new-approach-to-identifying-patients-with-elevated-risk-for-fabry-disease/)
- [MedTech Insights with Guests Rich Gliklich, MD and Neal Vachhani, MS](https://www.youtube.com/watch?v=kUcfy7wfd3s)
- [101 Most Innovative Boston Based Artificial Intelligence Companies](https://futurology.life/101-most-innovative-boston-based-artificial-intelligence-companies/)
- [101 Best United States Big Data Startups & Companies](https://datamagazine.co.uk/101-best-united-states-big-data-startups-companies/)
- [#Healthin2Point00, Episode 223 | Carbon Health, Woebot, Eight Sleep, Aidoc, and OM1](https://thehealthcareblog.com/blog/2021/07/22/healthin2point00-episode-223-carbon-health-woebot-eight-sleep-aidoc-and-om1/)
- [OM1 gains $85M to expand clinical data networks, AI models](https://medcitynews.com/2021/07/om1-gains-85m-to-expand-clinical-data-networks-ai-models/?rf=1)
- [RWD Powerhouse OM1 Announces $85 Million in Financing to Personalize Healthcare and Target Chronic Diseases](https://www.healtheconomics.com/industry-news/rwd-powerhouse-om1-announces-85-million-in-financing-to-personalize-healthcare-and-target-chronic-diseases)
- [AI startup OM1 bags $85M as Mass. VC deal activity reaches new high](https://www.bizjournals.com/boston/news/2021/07/16/ai-startup-om1-bags-85m-as-mass-vc-deal-activity.html)
- [Real-World Data & Technology Company OM1 Closes $85 Million Financing To Make Healthcare More Measured, Precise, And Pre-Emptive](https://www.prnewswire.com/news-releases/real-world-data--technology-company-om1-closes-85-million-financing-to-make-healthcare-more-measured-precise-and-pre-emptive-301335615.html?tc=eml_cleartime)
- [OM1 Launches Multiple Sclerosis Registry with More than 20,000 Patients Prospectively Followed with Deep Clinical Data](https://www.prnewswire.com/news-releases/om1-launches-multiple-sclerosis-registry-with-more-than-20-000-patients-prospectively-followed-with-deep-clinical-data-301333529.html?tc=eml_cleartime)
- [OM1 Rheumatoid Arthritis Registry Reaches More Than 200,000 Patients Prospectively Followed With Deep Clinical Data](https://www.prnewswire.com/news-releases/om1-rheumatoid-arthritis-registry-reaches-more-than-200-000-patients-prospectively-followed-with-deep-clinical-data-301271329.html?tc=eml_cleartime)
- [American Academy Of Dermatology Collaborates With OM1 To Empower More Measured & Precise Care And Treatments For Dermatology](https://www.prnewswire.com/news-releases/american-academy-of-dermatology-collaborates-with-om1-to-empower-more-measured--precise-care-and-treatments-for-dermatology-301264558.html?tc=eml_cleartime)
- [Dell Medical School helps develop artificial intelligence tool for knee surgery](https://www.statesman.com/story/news/healthcare/2021/04/02/dell-medical-school-ut-health-austin-use-computers-help-patients-make-knee-surgery-decision/7045802002/?utm_content=160748572&utm_medium=social&utm_source=linkedin&hss_channel=lcp-15179693)
- [Here are some of the best nicknames for workers at local companies](https://www.bizjournals.com/boston/news/2021/03/01/nicknames-local-workers-call-themselves.html?utm_content=155894532&utm_medium=social&utm_source=twitter&hss_channel=tw-1240331875421491201)
- [OM1 Artifical Intelligence (AI) Shared Decision Aid Demonstrates Significant Improvement In Decision Quality And Surgical Outcomes For Knee Osteoarthritis](https://www.prnewswire.com/news-releases/om1-artifical-intelligence-ai-shared-decision-aid-demonstrates-significant-improvement-in-decision-quality-and-surgical-outcomes-for-knee-osteoarthritis-301231185.html?tc=eml_cleartime)
- [OM1 Heart Failure Registry Reaches More than 140,000 Patients Prospectively Followed with Deep Clinical Data](https://www.prnewswire.com/news-releases/om1-heart-failure-registry-reaches-more-than-140-000-patients-prospectively-followed-with-deep-clinical-data-301216904.html?tc=eml_cleartime)
- [OM1 Giant Cell Arteritis Registry Reaches More Than 5,000 Patients Prospectively Followed With Deep Clinical Data](https://www.prnewswire.com/news-releases/om1-giant-cell-arteritis-registry-reaches-more-than-5-000-patients-prospectively-followed-with-deep-clinical-data-301188577.html?tc=eml_cleartime)
- [Registries for Evaluating Patient Outcomes: A User's Guide](/resources/ebooks/registries-user-guide/)
- [current and Future Use of HEOR in Decision Making](https://www.pm360online.com/current-and-future-use-of-heor-data-in-decision-making/?GTTabs=1)
- [Using real-world evidence to support a changing paradigm for cancer screening: A commentary](https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.5104)
- [OM1 Rheumatoid Arthritis Registry Reaches More Than 100,000 Patients Prospectively Followed with Deep Clinical Data](https://www.prnewswire.com/news-releases/om1-rheumatoid-arthritis-registry-reaches-more-than-100-000-patients-prospectively-followed-with-deep-clinical-data-300779329.html)
- [New Harmonized Outcome Measures for Atrial Fibrillation Published in HeartRhythm](https://www.prnewswire.com/news-releases/new-harmonized-outcome-measures-for-atrial-fibrillation-published-in-heartrhythm-300751140.html)
- [OM1 Lupus Registry Reaches More Than 25k Patients](https://www.medindia.net/health-press-release/om1-lupus-registry-reaches-more-than-25000-patients-prospectively-followed-with-deep-clinical-and-lab-data-388810-1.htm)
- [OM1: The Age of Personalized Medicine is Here](https://www.medindia.net/health-press-release/om1-lupus-registry-reaches-more-than-25000-patients-prospectively-followed-with-deep-clinical-and-lab-data-388810-1.htm)
- [Addendum to Registries for Evaluating Patient Outcomes: A User’s Guide, 3rd Edition](https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/biorepositories-registries-guide-3rd-ed-addendum-white-paper.pdf)